Galena Biopharma (SLS)
(Real Time Quote from BATS)
$1.34 USD
-0.03 (-2.19%)
Updated May 14, 2024 10:38 AM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SLS 1.34 -0.03(-2.19%)
Will SLS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLS
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLS
Sellas Life Sciences options imply 15.4% move in share price post-earnings
Solaris Resources Enhances Warintza Project Operations
Rare Stock Picks In April 2024 - From 28 Discerning Analysts
Solaris Provides Update on Warintza Operations, Optimization Progress, and Appointment of Leading Consultants for the EIA and PFS
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)